Massivemarkets

PCVX

Vaxcyte, Inc. Common Stock

Nasdaq · usd

$64.69-3.93 (-5.73%)
At close · 15-minute delayed
$65.63+0.94 (+1.45%)
As of 4:24:25 PM EST on Nov 12, 2026 · After hours

Vaxcyte, Inc. Common Stock (PCVX) trades at $64.69 (-5.73%) as of 4:24:25 PM EST on Nov 12, 2026, -4.23% over the past month. Market cap is $10.86B, with 6.7 days to cover in short interest.

Stock performance

How Vaxcyte, Inc. Common Stock (PCVX) stock has performed from one day to one year, with its 52-week range.

-4.48%
-$3.04 over 1D
$64.92$65.95$66.98$68.017:25 AM10:50 AM12:30 PM2:20 PM4:00 PM$64.69
1D
-5.73%
1W
+4.47%
1M
-4.23%
YTD
+40.20%
1Y
+42.02%
52-wk range
$42.40 – $90.75

Key statistics

Today's trading snapshot for PCVX: day range, open, previous close, volume and market cap.

Day range
$64.62 – $67.74
Open
$67.60
Prev close
$68.62
Volume
1.07M
Market cap
$10.86B
Shares out
158.3M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Vaxcyte, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
4.36
P/FCF
—
ROE
-46.1%
ROA
-38.4%
Debt/Equity
0.04
Div yield
0.00%

As of Nov 11, 2026

8-K filings

Material corporate events Vaxcyte, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.

  • Underwriting agreementOct 9, 2026

    On October 6, 2026, Vaxcyte entered into an underwriting agreement... relating to the issuance and sale... of 7,412,500 shares of Common Stock... and pre-funded warrants to purchase 400,000 shares of its Common Stock.

  • Investor presentationOct 5, 2026

    On October 5, 2026, the Company also made available the slide presentation attached as Exhibit 99.2 to this Current Report on Form 8-K.

  • Executive officer appointmentSep 3, 2026

    On August 31, 2026, Vaxcyte, Inc. (the "Company") appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.

  • Director appointmentJul 15, 2026

    Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026. Dr. Markels' term will expire at the Company's annual meeting of stockholders in 2028. The Board also appointed Dr. Markels to serve as a member of the Audit Committee and Compensation Committee of the Board.

PCVX short interest

How heavily PCVX is shorted: shares short, days to cover and average daily volume.

Days to cover
6.7
Short interest
15.36M
Avg volume
2.28M

As of · reported to FINRA twice monthly.

PCVX news

The latest news and headlines about Vaxcyte, Inc. Common Stock (PCVX).

Frequently asked questions

What is the Vaxcyte, Inc. Common Stock (PCVX) stock price today?

Vaxcyte, Inc. Common Stock (PCVX) is trading at $64.69 (-5.73% on the day) as of 4:24:25 PM EST on Nov 12, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Vaxcyte, Inc. Common Stock?

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine…

What is the short interest in PCVX?

As of Oct 30, 2026, PCVX has 15.36M shares short and 6.7 days to cover.

What exchange is PCVX listed on?

Vaxcyte, Inc. Common Stock (PCVX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of PCVX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a PCVX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.